 STOCKHOLM, Nov. 9, 2020 PRNewswire -- Calliditas Therapeutics AB OMX Nasdaq: CALTX NASDAQ: CALT Calliditas today announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon versus placebo in patients... 